Pharmaceutical and biotech product development consultancy Boyds has opened its US office in the Philadelphia area and welcomed Katy Rudnick as vice president and head of US Regulatory Affairs to head up the newly established US company.
The Curtis, located in the heart of Center City Philadelphia, once housed Curtis Publishing, owner of beloved publications such as the Saturday Evening Post and Ladies Home Journal.
The Jefferson Institute for Bioprocessing (JIB) is a jewel in the crown of Cellicon Valley. The institute provides critical training in biomanufacturing and bioprocessing for next-generation biologics, vaccines, and cell and gene therapies; skills that are in urgent demand by employers everywhere who are being challenged to find enough experienced employees to sustain their growth.
Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced the appointment of three new executive leaders including Scott Greenberg as Chief Operating Officer, Jeffrey Staiger as Senior Vice President of Finance and Business Development, and Michael Tortorici, PharmD, Ph.D. as Vice President of Clinical Pharmacology and Non-Clinical Development. Mr. Greenberg most recently served as Chief Business Officer of Aro, while Mr. Staiger and Dr. Tortorici are new additions to the leadership team. The Company also announced plans to move its headquarters to The Curtis in Philadelphia to accommodate ongoing growth of its operations and staff.
Over the years, minority input in the clinical development of life-saving drugs has been lacking, particularly when it comes to clinical trial participation. That has led to disparities in the efficacy of medications when taken by minority
Discovery Labs suburban Philadelphia campus gained a new tenant, the University of Pennsylvania Gene Therapy Program (GTP), which focuses on the development of AAV-based gene therapies for rare and orphan genetic diseases with high unmet needs.
ThruPore Technologies Inc., a market-disrupting, woman-led company with locations in Delaware and Alabama that is known for its Dr. Filter product, has chosen Newark as its site for expansion and continued innovation in chemistry and air filtration.
Philadelphia’s soaring life sciences commercial real estate market is being driven by the combination of strong demand for advanced lab and manufacturing facilities and near record low vacancy rates.
Gyroscope Therapeutics, a gene therapy company developing treatments for eye diseases, filed a Form F-1 with the U.S. Securities and Exchange Commission announcing its intention to begin selling American Depository Shares on the Nasdaq Exchange under the ticker symbol “VISN.” At the time of its filing this week, Gyroscope said it has not yet set the pricing terms for its stock. The $100 million is a placeholder figure. Based on positive clinical activity, and a recent financing round, the company is likely to raise significantly more than $100 million.
Code Biotherapeutics, a gene therapy company taking aim at rare diseases such as Duchenne Muscular Dystrophy, launched into the Greater Philadelphia gene therapy epicenter with $10 million in seed financing.
